Paper Details

  1. Home
  2. Paper Details

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.

Author: BendellJohanna, FeeneyKynan, GraciánAntonio Cubillo, HechtJ Randolph, HungAnnie, LeeMyung Ah, LinYong, LonardiSara, MuñozAndrés, RyooBaek-Yeol, WainbergZev A

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This systematic review assessed the safety and efficacy of FOLFOX for metastatic pancreatic cancer following prior gemcitabine-based therapy. A Bayesian meta-analysis was conducted to evaluate overall survival (OS) and compare outcomes with nanoliposomal irinotecan combination therapy. The review focused on providing evidence-based recommendations for treating pancreatic cancer patients who have previously received gemcitabine-based regimens.
Paper Details　
Original Abstract of the Article :
Pancreatic cancer has a poor prognosis and few choices of therapy. For patients with adequate performance status, FOLFIRINOX or gemcitabine plus nab-paclitaxel are preferred first-line treatment. 5-Fluorouracil (5-FU)-based therapy (e.g. FOLFIRI, OFF, or FOLFOX) are often used in patients who previo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346629/

データ提供：米国国立医学図書館（NLM）

Navigating the Sands of Pancreatic Cancer Treatment

Pancreatic cancer is a tough battle, often described as a desert of limited treatment options. This research delves into the world of second-line therapy for patients with pancreatic cancer who have already received gemcitabine-based treatment. It explores the effectiveness of 5-fluorouracil-based therapy, a common approach in these situations, and analyzes its impact on overall survival. The researchers also looked at the role of patient performance status and compared the outcomes with other second-line regimens.

Survival in the Pancreatic Cancer Desert

The study found that 5-fluorouracil-based therapy, particularly FOLFOX, can provide a valuable second-line option for patients with pancreatic cancer who have progressed after initial gemcitabine-based treatment. This gives patients a beacon of hope in a challenging landscape. The study also highlights the importance of patient performance status in determining treatment effectiveness, emphasizing the need for personalized care.

Finding Hope in the Pancreatic Cancer Landscape

This research offers valuable insights into the treatment of pancreatic cancer, a disease often associated with a bleak prognosis. It underscores the importance of finding the right treatment approach for each individual patient, based on their unique circumstances. While there is still much to learn about this complex disease, this research brings us closer to providing patients with the best possible care.

Dr. Camel's Conclusion

This research is like finding a hidden well in the middle of a vast and unforgiving desert. It offers hope for those facing pancreatic cancer by providing evidence-based insights into potential treatment options. It reminds us that even in the face of seemingly insurmountable challenges, there are always opportunities for progress and hope.

Date :
  1. Date Completed 2021-01-29
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

32641104

DOI: Digital Object Identifier

PMC7346629

Related Literature

Article Analysis
・Side Effects of leucovorin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.